Scinai Immunotherapeutics Ltd.
NasdaqCM SCNI
Scinai Immunotherapeutics Ltd. Free Cash Flow Yield on December 30, 2024: -234.54%
-
Scinai Immunotherapeutics Ltd. 52-week high Free Cash Flow Yield is -138.81% on July 15, 2024, which is 40.82% above the current Free Cash Flow Yield.
-
Scinai Immunotherapeutics Ltd. 52-week low Free Cash Flow Yield is -369.24% on June 12, 2024, which is -57.43% below the current Free Cash Flow Yield.
-
Scinai Immunotherapeutics Ltd. average Free Cash Flow Yield for the last 52 weeks is -232.88%.
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Amir Reichman M.B.A., M.Sc. |
| IPO Date | May 11, 2015 |
| Location | Israel |
| Headquarters | Jerusalem BioPark Building |
| Employees | 31 |
| Sector | Health Care |
| Industries | |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email